CGON
Cg Oncology, Inc.
A clinical-stage oncolytic immunotherapy company, CG Oncology develops genetically engineered viruses that selectively infect and destroy bladder cancer cells while rallying the body's immune system to attack tumors. Its lead candidate, cretostimogene, is designed to treat bladder cancer while sparing patients from bladder-removal surgery. Founded in California in 2010 as Cold Genesys — a name born from its virus-based technology — the company rebranded as CG Oncology in 2020, keeping "CG" as a nod to its origins.
CUSIP: 156944100HealthcareUS1 holder
Total Value
$11.04M
Total Shares
155.4K
Net Share Change
-31.0K
Activity
1 selling
Investor
Value
Shares
Weight
Change
